Long-term Remission of Acute Intermittent Porphyria Treated with Gonadotropin-Releasing Hormone Analogues and Estrogen: a Case Report

Clin Lab. 2022 Sep 1;68(9). doi: 10.7754/Clin.Lab.2022.211218.

Abstract

Background: Acute intermittent porphyria (AIP) is an autosomal dominant hepatic porphyria characterized by a partial deficiency of hydroxymethylbilane synthase involved in heme biosynthesis. It is difficult for all patients to achieve complete control of AIP episodes.

Method: We report on a 20-year-old female woman who suffered from recurrent abdominal pain and was diagnosed as "acute intermittent porphyria". She failed to respond to conventional symptomatic treatment and subsequently was treated with gonadotropin-releasing hormone analogues (GnRH) combined with estrogen for one year.

Result: The case did not experience acute attacks and obtained long-term clinical remission to date.

Conclusions: GnRH combined with estrogen, one of the treatment options for menstrual-associated AIP, might induce long-term remission.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Estrogens / therapeutic use
  • Female
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Heme
  • Humans
  • Hydroxymethylbilane Synthase*
  • Immunologic Factors
  • Porphyria, Acute Intermittent* / diagnosis
  • Porphyria, Acute Intermittent* / drug therapy
  • Young Adult

Substances

  • Estrogens
  • Immunologic Factors
  • Gonadotropin-Releasing Hormone
  • Heme
  • Hydroxymethylbilane Synthase